JP2018518511A - 細胞質ｄｎａ監視分子の調節方法 - Google Patents

細胞質ｄｎａ監視分子の調節方法 Download PDF

Info

Publication number
JP2018518511A
JP2018518511A JP2017566839A JP2017566839A JP2018518511A JP 2018518511 A JP2018518511 A JP 2018518511A JP 2017566839 A JP2017566839 A JP 2017566839A JP 2017566839 A JP2017566839 A JP 2017566839A JP 2018518511 A JP2018518511 A JP 2018518511A
Authority
JP
Japan
Prior art keywords
seq
sequence
hours
administration
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017566839A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018518511A5 (cg-RX-API-DMAC7.html
Inventor
イルク，トマス
アブラハム，アルバート
ニッケル，ジェイソン
カイル，ダニエル
ヴァイス，クリスティアン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Animal Health GmbH
Original Assignee
Bayer Animal Health GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Animal Health GmbH filed Critical Bayer Animal Health GmbH
Publication of JP2018518511A publication Critical patent/JP2018518511A/ja
Publication of JP2018518511A5 publication Critical patent/JP2018518511A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2017566839A 2015-06-26 2016-06-23 細胞質ｄｎａ監視分子の調節方法 Pending JP2018518511A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562185230P 2015-06-26 2015-06-26
US62/185,230 2015-06-26
PCT/EP2016/064613 WO2016207314A2 (en) 2015-06-26 2016-06-23 Methods of modulating cytosolic dna surveillance molecules

Publications (2)

Publication Number Publication Date
JP2018518511A true JP2018518511A (ja) 2018-07-12
JP2018518511A5 JP2018518511A5 (cg-RX-API-DMAC7.html) 2019-07-18

Family

ID=56235815

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017566839A Pending JP2018518511A (ja) 2015-06-26 2016-06-23 細胞質ｄｎａ監視分子の調節方法

Country Status (22)

Country Link
US (1) US20190233825A1 (cg-RX-API-DMAC7.html)
EP (1) EP3313376A2 (cg-RX-API-DMAC7.html)
JP (1) JP2018518511A (cg-RX-API-DMAC7.html)
KR (1) KR20180021874A (cg-RX-API-DMAC7.html)
CN (1) CN108472255A (cg-RX-API-DMAC7.html)
AR (1) AR105160A1 (cg-RX-API-DMAC7.html)
AU (1) AU2016282879A1 (cg-RX-API-DMAC7.html)
BR (1) BR112017028121A2 (cg-RX-API-DMAC7.html)
CA (1) CA2990526A1 (cg-RX-API-DMAC7.html)
CL (1) CL2017003373A1 (cg-RX-API-DMAC7.html)
CR (1) CR20180003A (cg-RX-API-DMAC7.html)
DO (1) DOP2017000313A (cg-RX-API-DMAC7.html)
HK (1) HK1256128A1 (cg-RX-API-DMAC7.html)
IL (1) IL256264A (cg-RX-API-DMAC7.html)
MX (1) MX2017017141A (cg-RX-API-DMAC7.html)
PE (1) PE20181208A1 (cg-RX-API-DMAC7.html)
PH (1) PH12017502413A1 (cg-RX-API-DMAC7.html)
RU (1) RU2018102915A (cg-RX-API-DMAC7.html)
SG (1) SG10201913395VA (cg-RX-API-DMAC7.html)
TW (1) TW201710509A (cg-RX-API-DMAC7.html)
UY (1) UY36756A (cg-RX-API-DMAC7.html)
WO (1) WO2016207314A2 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016081911A2 (en) 2014-11-21 2016-05-26 Northwestern University The sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates
EP3490598A1 (en) 2016-07-26 2019-06-05 Bayer Animal Health GmbH Increased fertility in bovine species
US11364304B2 (en) 2016-08-25 2022-06-21 Northwestern University Crosslinked micellar spherical nucleic acids
WO2018209270A1 (en) 2017-05-11 2018-11-15 Northwestern University Adoptive cell therapy using spherical nucleic acids (snas)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6693086B1 (en) * 1998-06-25 2004-02-17 National Jewish Medical And Research Center Systemic immune activation method using nucleic acid-lipid complexes
WO2004050872A1 (en) * 2002-12-02 2004-06-17 Women's And Children's Hospital Modified lacz gene
JP2008509677A (ja) * 2004-08-13 2008-04-03 ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア 抗生物質耐性欠失ワクチンの作成方法
JP2008511545A (ja) * 2004-08-13 2008-04-17 ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア 抗生物質耐性欠失ｄｎａワクチン
JP2014500292A (ja) * 2010-12-22 2014-01-09 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング ウシの種における免疫応答の増強
JP2017512202A (ja) * 2014-02-28 2017-05-18 バイエル・アニマル・ヘルス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ａｎｉｍａｌ Ｈｅａｌｔｈ Ｇｍｂｈ 免疫賦活プラスミド

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US155950A (en) * 1874-10-13 Improvement in hand-saws
CA2560114A1 (en) * 1994-07-15 1996-02-01 The University Of Iowa Research Foundation Immunomodulatory oligonucleotides
EP1003531B1 (en) * 1997-05-20 2007-08-22 Ottawa Health Research Institute Processes for preparing nucleic acid constructs
AU2001296354A1 (en) * 2000-09-25 2002-04-02 Baylor College Of Medicine Improved system for regulation of transgene expression
WO2005033265A2 (en) * 2003-04-25 2005-04-14 Epimmune Inc. Optimized multi-epitope constructs and uses thereof
CL2004001293A1 (es) * 2003-05-29 2005-05-06 Schering Plough Ltd Composicion farmaceutica que comprende compuestos antibacterianos como florfenicol, tiamfenicol, cloramfenicol en combinacion con al menos un portador seleccionado de triacetina, dimetilacetamida o una mezcla de ellas; y su uso en el tratamiento de u
US20120064151A1 (en) * 2009-05-14 2012-03-15 Bayer Animal Health Gmbh Enhanced immune response in avian species
BR112013029968A2 (pt) * 2011-05-26 2017-01-31 Intervet Int Bv oligodesoxinucleotídeo imunoestimulatório não metilado, vetor, vacina para prevenir ou combater uma doença infecciosa, e, método para a detecção de oligodesoxinucleotídeos imunoestimulatórios
AR091569A1 (es) * 2012-06-28 2015-02-11 Intervet Int Bv Receptores de tipo toll

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6693086B1 (en) * 1998-06-25 2004-02-17 National Jewish Medical And Research Center Systemic immune activation method using nucleic acid-lipid complexes
WO2004050872A1 (en) * 2002-12-02 2004-06-17 Women's And Children's Hospital Modified lacz gene
JP2008509677A (ja) * 2004-08-13 2008-04-03 ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア 抗生物質耐性欠失ワクチンの作成方法
JP2008511545A (ja) * 2004-08-13 2008-04-17 ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア 抗生物質耐性欠失ｄｎａワクチン
JP2014500292A (ja) * 2010-12-22 2014-01-09 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング ウシの種における免疫応答の増強
JP2017512202A (ja) * 2014-02-28 2017-05-18 バイエル・アニマル・ヘルス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ａｎｉｍａｌ Ｈｅａｌｔｈ Ｇｍｂｈ 免疫賦活プラスミド

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
"Protocol Reviews #0808-394 and #0808-936", RECOMBINANT DNA ADVISORY COMMITTEE, JPN6021017057, 2008, ISSN: 0004656043 *
ANTIVIRAL RESEARCH, vol. p. 165-172, JPN6020026754, 2006, ISSN: 0004656042 *
ANTIVIRAL RESEARCH, vol. Vol. 81, Issue 1, JPN6020026753, 2009, pages 37 - 46, ISSN: 0004656041 *
G.CHIKH; ET AL: "SYNTHETIC METHYLATED CPG ODNS ARE POTENT IN VIVO ADJUVANTS WHEN DELIVERED IN LIPOSOMAL NANOPARTICLES", INTERNATIONAL IMMUNOLOGY, vol. VOL:21, NR:7, JPN5018003802, 5 June 2009 (2009-06-05), GB, pages 757 - 767, ISSN: 0004502256 *
KOUJI KOBIYAMA; ET AL: "INNATE IMMUNE SIGNALING BY, AND GENETIC ADJUVANTS FOR DNA VACCINATION", VACCINES, vol. VOL:1, NR:3, JPN5018003805, 18 July 2013 (2013-07-18), pages 278 - 292, ISSN: 0004502257 *

Also Published As

Publication number Publication date
PH12017502413A1 (en) 2018-06-25
AR105160A1 (es) 2017-09-13
UY36756A (es) 2017-01-31
PE20181208A1 (es) 2018-07-23
CL2017003373A1 (es) 2018-06-29
AU2016282879A1 (en) 2018-01-18
TW201710509A (zh) 2017-03-16
BR112017028121A2 (pt) 2018-09-04
MX2017017141A (es) 2018-03-09
CN108472255A (zh) 2018-08-31
WO2016207314A3 (en) 2017-02-09
EP3313376A2 (en) 2018-05-02
CR20180003A (es) 2018-03-20
CA2990526A1 (en) 2016-12-29
DOP2017000313A (es) 2018-02-28
KR20180021874A (ko) 2018-03-05
WO2016207314A2 (en) 2016-12-29
RU2018102915A (ru) 2019-07-29
RU2018102915A3 (cg-RX-API-DMAC7.html) 2019-12-05
HK1256128A1 (zh) 2019-09-13
IL256264A (en) 2018-02-28
US20190233825A1 (en) 2019-08-01
SG10201913395VA (en) 2020-03-30

Similar Documents

Publication Publication Date Title
JP6058550B2 (ja) ウシの種における免疫応答の増強
US10851379B2 (en) Immunostimulatory plasmids
JP2018518511A (ja) 細胞質ｄｎａ監視分子の調節方法
US11439703B2 (en) Enhanced immune response in porcine species
TWI759317B (zh) 牛物種中增加的生育力
TWI733688B (zh) 水生物種中增強之免疫反應
HK1190628A (en) Enhanced immune response in bovine species

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190614

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190614

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200728

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20201022

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210127

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210511

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20211207